(MENAFN- AFP) Britain on Monday granted its first research licence to genetically modify human embryos to a project that aims to give hope to women struggling to conceive, raising ethical concerns about "designer babies".
The decision makes Britain one of the first countries in the world to grant this type of authorisation on one of science's new frontiers and follows months of deliberation by the British embryology regulator.
The Human Fertilisation and Embryology Authority (HFEA) said it had approved an application from Dr Kathy Niakan of the Francis Crick Institute for a new laboratory research licence "to include gene editing of embryos".
Researchers explained that the embryos used will be spare ones donated by women receiving In Vitro Fertilisation (IVF) treatment who do not need them.
Any modified embryos have to be destroyed within 14 days and cannot be implanted in a woman. The research will examine embryos in their first few days.
"Dr Niakan's proposed research is important for understanding how a healthy human embryo develops and will enhance our understanding of IVF success rates," said Paul Nurse, director of the Crick Institute.
- No 'moral panic' -
The project, which could start within months, would use CRISPR-Cas9, a technique allowing scientists to insert, remove and correct DNA within a cell.
The technique was developed by US chemistry professor Jennifer Doudna and Emmanuelle Charpentier of France and could also be used to treat illnesses like sickle cell diseases, cystic fibrosis and some cancers.
Charpentier told AFP last year the technique was "a little bit like a Swiss knife that cuts DNA at a precise point and can be used to introduce a series of changes in the genome of a call or an organism".
In a research paper published in April, Chinese scientists described how they were able to manipulate the genomes of human embryos for the first time using CRISPR-Cas9, raising ethical concerns.
Campaigners criticised Monday's decision.
"This is the first step in a well mapped-out process leading to GM babies, and a future of consumer eugenics," said David King, director of the watchdog group Human Genetics Alert.
A UNESCO panel of scientists, philosophers, lawyers and ministers last year called for a halt to genetic "editing", warning of the danger of tampering with hereditary traits that could lead to eugenics.
UNESCO's International Bioethics Committee (IBC) said gene therapy could be "a watershed in the history of medicine" and genome editing "is unquestionably one of the most promising undertakings of science for the sake of all humankind."
But the experts warned that genetic editing required "particular precautions" and raised "serious concerns".
There were particular grounds for concerns if the modifications "introduce hereditary modifications, which could be transmitted to future generations," they said.
But many researchers welcomed the ruling.
The project should "assist infertile couples and reduce the anguish of miscarriage," Bruce Whitelaw, professor of animal biotechnology at the University of Edinburgh, told the Science Media Centre.
Darren Griffin, professor of genetics at the University of Kent, said the ruling was "a triumph for common sense".
"While it is certain that the prospect of gene editing in human embryos raised a series of ethical issues and challenges, the problem has been dealt with in a balanced manner," he said.
"It is a clear example how the UK leads the world not only in the science behind research into early human development but also the social science used to regulate and monitor it," he added.
Sarah Norcross, director of Progress Educational Trust, a charity, said: "This decision by the HFEA is a victory for level-headed regulation over moral panic".
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.